Acorai
Helsingborg
About Acorai
Acorai is building a non-invasive heart failure monitoring platform with direct intracardiac pressure monitoring (ICPM) at its core. Acorai offers accurate and cost-efficient heart failure care using patented technology that leverages a novel combination of sensor technologies and machine learning to enable non-invasive ICPM, the only proven way to improve outcomes in HF patients. The device has been clinically validated, designated FDA Breakthrough Device, and will enter the market in 2025. The company's product can non-invasively monitor cardiac and pulmonary pressure by utilizing machine-learning techniques to analyze pressure dynamics in acoustic, vibratory, and waveform data.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.8M
- Last round: Series Unknown (Feb 2025)
- Website: acorai.com
- Phone: +46708756781
Industries & Categories
Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/acorai-97651 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.